New Hampshire’s PBM law (RSA 402-N, effective January 1, 2020) is a registration-and-transparency regime, not a reimbursement floor. PBM contracts must disclose the sources used to calculate drug reimbursement and the pricing compendia behind MAC, and must provide a MAC appeal — at least 30 business days to file and a 30-business-day resolution window.
A bill that would have required NADAC as a pricing point of reference (HB 1580) was found “inexpedient to legislate” in 2022 and never became law. Some summaries still attribute a NADAC requirement to New Hampshire; the codified statute contains none.